Short answer
EyePoint, Inc. (EYPT) filed an 8-K current report with the SEC on September 10, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Updated investor presentation posted September 10, 2026.
EyePoint, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Updated investor presentation posted September 10, 2026
- Exhibit 99.1 contains the presentation and may include updated business, pipeline, or financial information
- Investors should review the exhibit for material changes to EyePoint’s outlook
Item EX-99.1 · Exhibit EX-99.1
- LUGANO missed full-population non-inferiority, a major regulatory setback despite strong anatomic control and durability
- Nine DURAVYU-arm eyes lost ≥15 letters from non-wet-AMD causes, driving the endpoint; excluding them achieved non-inferiority with nominal p=0.0096
- Treatment burden fell 42% versus aflibercept, with 54% supplement-free and 88% requiring two or fewer supplements through Week 56
- Safety remained favorable with repeat dosing; no retinal vasculitis, severe inflammation, or anterior-chamber migration reported
- Investor focus shifts to LUCIA Phase 3 data expected Q4 2026 and potential wet-AMD NDA filing targeted for 1H 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other EyePoint, Inc. 8-K filings
Get the next EYPT 8-K as it lands
Follow EYPT for push alerts, or ask the research agent what this filing means.